S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Small A.I. Firm Wins $2 Billion in Contracts for Breakthrough "Living Software" (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
Small A.I. Firm Wins $2 Billion in Contracts for Breakthrough "Living Software" (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
What is the Penalty for Excess Contributions to an IRA?
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Small A.I. Firm Wins $2 Billion in Contracts for Breakthrough "Living Software" (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
Small A.I. Firm Wins $2 Billion in Contracts for Breakthrough "Living Software" (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
What is the Penalty for Excess Contributions to an IRA?
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Small A.I. Firm Wins $2 Billion in Contracts for Breakthrough "Living Software" (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
Small A.I. Firm Wins $2 Billion in Contracts for Breakthrough "Living Software" (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
What is the Penalty for Excess Contributions to an IRA?
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Small A.I. Firm Wins $2 Billion in Contracts for Breakthrough "Living Software" (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
Small A.I. Firm Wins $2 Billion in Contracts for Breakthrough "Living Software" (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
What is the Penalty for Excess Contributions to an IRA?
NASDAQ:NYXH

Nyxoah (NYXH) Competitors

$8.11
+0.45 (+5.87%)
(As of 06/1/2023 ET)
Compare
Today's Range
$7.84
$8.22
50-Day Range
$6.80
$10.34
52-Week Range
$4.36
$14.63
Volume
2,136 shs
Average Volume
22,695 shs
Market Capitalization
$202.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00

NYXH vs. INO, XAIR, KRMD, HSAQ, INFU, BVS, ALPA, CLPT, APYX, and CTSO

Should you be buying Nyxoah stock or one of its competitors? The main competitors of Nyxoah include Inovio Pharmaceuticals (INO), Beyond Air (XAIR), KORU Medical Systems (KRMD), Health Sciences Acquisitions Co. 2 (HSAQ), InfuSystem (INFU), Bioventus (BVS), Alpha Healthcare Acquisition Corp. III (ALPA), ClearPoint Neuro (CLPT), Apyx Medical (APYX), and Cytosorbents (CTSO). These companies are all part of the "surgical & medical instruments" industry.

Nyxoah vs.

Nyxoah (NASDAQ:NYXH) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, community ranking, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Nyxoah has higher earnings, but lower revenue than Inovio Pharmaceuticals. Nyxoah is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nyxoah$3.25 million62.23-$32.90 million-$1.46-5.55
Inovio Pharmaceuticals$10.26 million14.65-$279.82 million-$0.98-0.58

Inovio Pharmaceuticals received 705 more outperform votes than Nyxoah when rated by MarketBeat users. Likewise, 73.68% of users gave Inovio Pharmaceuticals an outperform vote while only 42.86% of users gave Nyxoah an outperform vote.

CompanyUnderperformOutperform
NyxoahOutperform Votes
9
42.86%
Underperform Votes
12
57.14%
Inovio PharmaceuticalsOutperform Votes
714
73.68%
Underperform Votes
255
26.32%

11.5% of Nyxoah shares are owned by institutional investors. Comparatively, 46.4% of Inovio Pharmaceuticals shares are owned by institutional investors. 17.1% of Nyxoah shares are owned by company insiders. Comparatively, 2.0% of Inovio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Nyxoah has a net margin of -1,270.87% compared to Inovio Pharmaceuticals' net margin of -2,371.71%. Nyxoah's return on equity of -28.01% beat Inovio Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Nyxoah -1,270.87% -28.01% -23.05%
Inovio Pharmaceuticals -2,371.71% -97.93% -65.84%

In the previous week, Nyxoah and Nyxoah both had 1 articles in the media. Inovio Pharmaceuticals' average media sentiment score of 0.91 beat Nyxoah's score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nyxoah
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Inovio Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Nyxoah presently has a consensus target price of $13.00, suggesting a potential upside of 60.30%. Inovio Pharmaceuticals has a consensus target price of $2.00, suggesting a potential upside of 249.65%. Given Inovio Pharmaceuticals' higher possible upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Nyxoah.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nyxoah
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Inovio Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.75

Nyxoah has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.

Summary

Nyxoah beats Inovio Pharmaceuticals on 9 of the 17 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NYXH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NYXH vs. The Competition

MetricNyxoahSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$202.26M$3.55B$4.54B$5.82B
Dividend YieldN/A2.96%2.42%6.15%
P/E Ratio-5.5534.29123.0113.35
Price / Sales62.2327.723,636.7495.76
Price / CashN/A64.2790.91108.31
Price / Book1.515.155.157.27
Net Income-$32.90M$59.42M$117.90M$175.81M
7 Day Performance4.11%1.67%3.21%2.63%
1 Month Performance-7.00%-2.30%3.14%3.13%
1 Year Performance-31.24%-8.64%23.04%1.81%

Nyxoah Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INO
Inovio Pharmaceuticals
2.2578 of 5 stars
$0.66
-1.5%
$2.00
+202.4%
-67.5%$173.78M$10.26M-0.67317Positive News
XAIR
Beyond Air
1.9499 of 5 stars
$5.65
-1.6%
$21.50
+280.5%
-7.2%$170.01M$870,000.00-2.9341
KRMD
KORU Medical Systems
1.6636 of 5 stars
$3.72
-2.6%
$4.17
+12.0%
+73.9%$169.67M$27.90M-19.5877Positive News
HSAQ
Health Sciences Acquisitions Co. 2
0 of 5 stars
$15.11
-5.6%
N/A+64.4%$169.41MN/A0.004
INFU
InfuSystem
0 of 5 stars
$8.75
-3.8%
N/AN/A$183.14M$109.91M0.00N/A
BVS
Bioventus
2.1695 of 5 stars
$2.43
+16.3%
$5.50
+126.3%
-68.4%$189.66M$512.12M-0.521,120Positive News
ALPA
Alpha Healthcare Acquisition Corp. III
0 of 5 stars
$10.23
flat
N/AN/A$197.54MN/A0.002,021
CLPT
ClearPoint Neuro
1.6663 of 5 stars
$8.22
-1.7%
$14.00
+70.3%
-30.8%$202.05M$20.55M-11.1167
APYX
Apyx Medical
1.309 of 5 stars
$5.98
-0.7%
$6.33
+5.9%
+17.1%$206.91M$44.51M-9.97272
CTSO
Cytosorbents
1.6636 of 5 stars
$3.04
-4.4%
$5.50
+80.9%
+64.8%$133.62M$29.35M-4.28221

Related Companies and Tools

This page (NASDAQ:NYXH) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -